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Key Concepts • Because of combustion of fossil fuels and organic waste, PAHs 
are ubiquitous in the environment 
• Studies show that certain PAH metabolites interact with DNA and 
are genotoxic, causing malignancies and heritable genetic 
damage in humans. 
• In humans, heavy occupational exposure to mixtures of PAHs 
entails a substantial risk of lung, skin, or bladder cancer. 
About This and 
Other Case Studies 
in Environmental 
Medicine 
This educational case study document is one in a series of self-
instructional modules designed to increase the primary care 
provider’s knowledge of hazardous substances in the environment 
and to promote the adoption of medical practices that aid in the 
evaluation and care of potentially exposed patients. The complete 
series of Case Studies in Environmental Medicine is located on the 
ATSDR Web site at http://www.atsdr.cdc.gov/csem/. In addition, 
the downloadable PDF version of this educational series and other 
environmental medicine materials provides content in an electronic, 
printable format, especially for those who may lack adequate 
Internet service. 




See Internet address www.atsdr.cdc.gov/csem/conteduc.html for 
more information about continuing medical education credits, 
continuing nursing education credits, and other continuing education 
units. 
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How to Use This Course 
Introduction The goal of Case Studies in Environmental Medicine (CSEM) is to increase 
the primary care provider’s knowledge of hazardous substances in the 
environment and to help in evaluation and treating of potentially exposed 
patients. This CSEM focuses on the toxicity of polycyclic aromatic 
hydrocarbons. 




• The HTML version http://www.atsdr.cdc.gov/csem/pah/ provides 
content through the Internet. 
• The downloadable PDF version provides content in an electronic, 
printable format, especially for those who may lack adequate 
Internet service. 
The HTML version offers interactive exercises and prescriptive feedback 
to the user. 
Instructions To make the most effective use of this course. 
• Take the Initial Check to assess your current knowledge about the 
toxicity of polycyclic aromatic hydrocarbons. 
• Read the title, learning objectives, text, and key points in each 
section. 
• Complete the progress check exercises at the end of each section 
and check your answers. 
• Complete and submit your assessment and posttest response 
online if you wish to obtain continuing education credit. Continuing 
education certificates can be printed immediately upon completion. 
Instructional 
Format 
This course is designed to help you learn efficiently. Topics are clearly 
labeled so that you can skip sections or quickly scan sections you are 
already familiar with. This labeling will also allow you to use this training 
material as a handy reference. To help you identify and absorb important 
content quickly, each section is structured as follows: 
 
Section Element Purpose 
Title Serves as a “focus question” that you should be able to answer 
after completing the section 
Learning Objectives Describes specific content addressed in each section and focuses 
your attention on important points 
Text Provides the information you need to answer the focus question(s) 
and achieve the learning objectives 
Key Points Highlights important issues and helps you review 
Progress Check Enables you to test yourself to determine whether you have 
mastered the learning objectives 
Answers Provide feedback to ensure you understand the content and can 
locate information in the text 
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Upon completion of the Toxicity of Polycyclic Aromatic Hydrocarbons 
(PAH) CSEM, you will be able to 
 
Content Area Objectives 
Overview • explain what PAHs are 
• describe the properties of PAHs 
• identify where PAHs are found 
Exposure Pathways • identify routes of exposure to PAHs 
Who is at Risk • identify the populations at high risk for exposure to PAHs 
Standards and 
Regulations 
• describe the Occupational Safety and Health 
Administration’s permissible exposure limit (PEL) for PAHs 
• describe the U.S. Environmental Protection Agency’s 
maximum contaminant level (MCL) for PAHs in drinking 
water 
Biological Fate • describe the biologic fate of PAHs in the body 
Pathogenic Changes • describe how PAHs are believed to induce pathogenic 
changes 
Health Effects • describe health effects associated with PAH exposure 
Clinical Assessment • describe typical signs and symptoms of patients with acute 
PAH exposure 
• describe typical signs and symptoms of patients with 
chronic PAH exposure 
• describe  important elements of the exposure history 
• describe the focus of the physical examination 
• describe tests used to assist in evaluation of patients 
exposed to PAHs 
Treatment and 
Management 
• identify strategies for managing patients with chronic PAH 
exposure 
Patient Education and 
Counseling 
• describe care advice for the patient exposed to PAHs  
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Initial Check 
Instructions This Initial Check will help you assess your current knowledge about the 
toxicity of polycyclic aromatic hydrocarbons (PAH). To take the Initial 
Check, read the case below, and then answer the questions that follow. 
Case Study Dyspnea, weight loss, and weakness in a 52-year-old male coal 
tar manufacturing plant worker 
A 52-year-old man comes to your office for a health evaluation, his first 
in 3 years. While trying to assure you that he is in reasonably good 
health, he admits that his wife prompted this visit. She is concerned 
about his weight loss, lack of stamina, and weakness in the shoulders 
and arms. When you review his chart, you see that he has lost 30 
pounds since his last visit. The patient also describes shortness of breath 
with moderate activity. He is a lifelong nonsmoker and drinks alcohol 
only occasionally. He is taking no medications. His past medical history is 
noncontributory. A review of systems reveals that the patient also has a 
chronic, intermittently productive cough, which has been ongoing for 1 
month. 
The patient has worked at a coal tar manufacturing plant for the past 34 
years. He has been a lifelong resident of an urban industrial 
neighborhood that is approximately 1 mile from where he works. He has 
been married for 25 years. His wife and adult daughter are in good 
health. 
A physical examination shows that his vital signs are normal. An 
inspection of his skin reveals multiple dry, scaly, hyperpigmented 
macules involving the forehead, temporoparietal areas, eyelids, and 
brows, and several hyperkeratotic papillomata on his face, neck, upper 
chest, forearms, and hands. Palpation of the right supraclavicular area 
reveals a firm, nontender, fixed lymph node 2 x 3 centimeters (cm) in 
size. Auscultation discloses intermittent, scattered, right-sided wheezes 
and dry bibasilar crackles. The remainder of the exam is unremarkable. 
The patient’s laboratory results are remarkable for the following: 
1. hemoglobin = 12.9 grams per deciliter (g/dL) (normal = 14–18 
g/dL); 
2. hematocrit = 36% (normal = 42%–52%); 
3. leukocyte count = 2.9 x 103 per microliter (µL) (normal = 3.9–11 x 
103/µL);  
4. serum calcium = 12.9 milligrams per deciliter (mg/dL) (normal = 
8.5–10.5 mg/dL);  
5. alkaline phosphatase = 483 international units per liter (IU/L) 
(normal = 30–125 IU/L) with concomitant elevation of GGTP 
(GGT);  
6. SGOT (AST) 121 IU/L (normal = 7–45); 
7. SGPT (ALT) 129 IU/L (normal = 7–35 IU/L);  
8. The chest radiograph reveals a 3.3-cm central, thick-walled, 
cavitating lesion with irregular, spicular margins in the right upper 
lobe, and atelectasis and prominence of the right hilar lymphatics. 
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Initial Check 1. What are likely sources of PAHs for the patient described in the case 
study? 
2. Besides the patient, who in the case study might be at risk for PAH 
exposure? 
3. The patient’s daughter, who has lived in his household all of her life, 
recently gave birth to a daughter. Is the newborn at risk for PAH 
exposure? Why or why not? 
4. How could you document that the work environment of the patient 
described in the case study contributed to his risk of lung cancer? 
5. Before his present employment, the patient in the case study was 
employed as a laborer on a farm. He says that he was not exposed to 
pulmonary toxic agents such as asbestos or silica. What is the 
problem list and the differential diagnosis for this patient? 
6. The diagnosis for the patient described in the case study is squamous 
cell carcinoma of the lung. In general, what can you do to decrease 
the risk for lung cancer among your patients? 
7. Would you consider the patient described in the case study a sentinel 
case requiring notification of public health agencies? Explain. 
Initial Check 
Answers 
1. The patient may have been exposed to coal tar manufacturing 
pollutants at his work for more than 34 years. Moreover, if his home 
is in the prevailing downwind direction from the coal tar 
manufacturing plant, pollutants might contribute to ambient air 
contamination near his home. However, environmental studies 
related to air pollution are more complex and must separate out 
contaminants from indoor cooling/heating systems, environmental 
tobacco smoke, urban air pollution, and other sources. The patient 
might have been exposed to PAH mixtures by all three routes: 
inhalation, ingestion, and direct cutaneous contact. 
More information for this answer can be found in the “What Are 
Routes of Exposure to PAHs?” and “Who Is at Risk of Exposure to 
PAHs?” sections. 
2. Workers at the coal tar manufacturing plant and residents in the 
community downwind from the plant might be exposed to PAH 
mixtures. However, other contributors to environmental ambient air 
contamination should be kept in mind, including environmental 
tobacco smoke, indoor cooking and heating practices, and urban air 
pollution. The patient’s family members might be at risk for additional 
exposure if the patient carried these compounds home on his skin 
and work clothes. 
More information for this answer can be found in the “What Are 
Routes of Exposure to PAHs?” and “Who Is at Risk of Exposure to 
PAHs?” sections. 
3. The patient’s newborn granddaughter may be at risk for PAH 
exposure. If the patient’s daughter breathed contaminated air in and 
around the house, then the baby could have been exposed in utero. 
This exposure could have occurred while the patient’s daughter was 
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doing various household chores, such as laundering, dusting, and 
general cleaning of the contaminated home or her father’s work 
clothing. Based on animal studies, PAH mixtures absorbed into the 
mother’s system might continue to be transferred to the baby via 
breast milk. The baby might also be breathing contaminated air, 
thereby increasing her exposure. 
More information for this answer can be found in the “Who Is at Risk 
of Exposure to PAHs?” section. 
4. The role of the workplace in the patient’s PAH mixture exposure can 
be determined by area sampling at the work site, individual 
monitoring, medical surveillance of coworkers, and air sampling 
within the immediate community. Industrial hygienists would typically 
perform these activities.  Data may be available through sources at 
the coal tar manufacturing plant and at local, state, or federal 
agencies.  
More information for this answer can be found in the “Who Is at Risk 
of Exposure to PAHs” section. 
5. The patient’s problem list includes weight loss, fatigue, muscle 
weakness, skin lesions on exposed areas, exertional dyspnea, and a 
roentgenographically identified cavitating lesion in the right upper 
lobe with associated lymphadenopathy. The differential diagnosis 
includes carcinoma of the lung, tuberculosis, fungal lung infection, 
and lung abscess. 
More information for this answer can be found in the “What Health 
Effects are Associated with PAH Exposure” and “Clinical 
Assessment.”” sections. 
6. The main objective is to educate patients about cancer prevention. 
You should try to stimulate changes in their work habits and lifestyle 
that will decrease the risk for cancer. A risk assessment can identify 
elements in a person’s workplace, family history, medical history, and 
lifestyle that might be controllable risk factors. 
For example, between 75% and 80% of all cases of bronchogenic 
carcinoma are due to cigarette smoking and are therefore 
preventable. Of the remaining 20%–25%, many are related to 
occupation or the environment and could therefore be prevented by 
appropriate workplace or environmental controls. The incidence of 
lung cancer might also be decreased through education efforts that 
focus on 
• smoking prevention, 
• improving working conditions, 
• substitution of less-hazardous materials in work processes and 
building materials, and 
• increased awareness of personal risk factors. 
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More information for this answer can be found in the “What 
Instructions Should Be Given to Patients Exposed to PAHs?” 
section. 
7. In view of the patient’s medical, social, occupational, and family 
history, the workplace and environmental factors emerge as the most 
likely causal factors in the development of his neoplastic disease. 
When the potential exists for others to be exposed, serious illness 
related to occupational or environmental factors should be reported to 
the appropriate state and federal authorities. For example, OSHA 
would have responsibility for PAHs in the workplace air at the coal tar 
manufacturing site. EPA would have responsibility for the level of 
emissions to the ambient air or water. Inclusion of this case in a 
tumor registry should also be considered. 
More information for this answer can be found in the “Clinical 
Assessment” and “How Should Patients Exposed to PAHs be Treated 
and Managed?” sections. 
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What Are Polycyclic Aromatic Hydrocarbons (PAHs)? 
Learning 
Objective 
Upon completion of this section, you will be able to 
• explain what PAHs are, and  
• describe the properties of PAHs. 
Definition PAHs are a class of organic compounds produced by incomplete 
combustion or high-pressure processes. PAHs form when complex 
organic substances are exposed to high temperatures or pressures. 
Often, PAHs consist of three or more fused benzene rings containing only 
carbon and hydrogen (Figure 1). Differences in the configuration of 
rings may lead to differences in properties. 
 
Figure 1. Structural formulas of selected polycyclic aromatic 
hydrocarbons (PAHs). The arrows indicate bay regions. 
Synonyms 
 
PAHs are known by several names: 
• polycyclic organic matter (POM), 
• polynuclear aromatic hydrocarbons, 
• polynuclear aromatics (PNAs), and 
• polynuclear hydrocarbons. 
The more common PAHs include 
• benzo(a)anthracene, 
Page 9 of 68 
Agency for Toxic Substances and Disease Registry (ATSDR) 
Case Studies in Environmental Medicine 













• are solids with low volatility at room temperature, 
• have relatively high molecular weights,  
• are soluble in many organic solvents,  
• are relatively insoluble in water, and  
• most can be photo-oxidized and degraded to simpler substances. 
Key Points • PAHs are a class of organic compounds produced by incomplete 
combustion or high-pressure processes. 
• Often, PAHs consist of three or more fused benzene rings containing 
only carbon and hydrogen. 
• PAHs are solids with low volatility at room temperature. They are 
relatively insoluble in water, and most can be photo-oxidized and 
degraded to simpler substances. 
Progress 
Check 
1. Which of the following is (are) true regarding PAHs? 
A. PAHs comprise a class of organic compounds produced by high-
pressure processes. 
B. Often, PAHs consist of three or more fused benzene rings 
containing only hydrogen and carbon. 
C. PAHs comprise a class of organic compounds produced from 
incomplete combustion. 
D. All of the above. 
To review relevant content, see “Definition” in this section. 
2. Which of the following is (are) true regarding PAHs? 
A. They are water-soluble. 
B. They have relatively low molecular weights. 
C. They are solids with low volatility at room temperature. 
D. All of the above. 
To review relevant content, see “Properties” in this section. 
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Answers 1. The correct true answer is D. PAHs are a class of organic compounds 
produced from incomplete combustion or high-pressure processes 
and consist of three or more fused benzene rings containing only 
hydrogen and carbon. 
2. The correct true answer is C. PAHs are solids with low volatility at 
room temperature. The remaining choices are false because PAHs 
are relatively insoluble in water and have relatively high molecular 
weights. 
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Where Are Polycyclic Aromatic Hydrocarbons (PAHs) Found? 
Learning 
Objective 
Upon completion of this section, you will be able to 
•  identify where PAHs are found. 
Introduction PAHs are ubiquitous in the environment and are common byproducts of 
combustion processes. PAHs are a natural component of most fossil 
fuels. 
Although produced naturally by forest fires and volcanoes, most PAHs in 
ambient air are the result of man-made processes. Such processes 
include 
• burning fuels such as coal, wood, petroleum, petroleum products, 
or oil, 
• burning refuse, used tires, polypropylene, or polystyrene, 
• coke production, and 
• motor vehicle exhaust [Cherng et al. 1996; Lewitas 1997]. 
There are approximately 100 different known PAHs in air, soil, foodstuffs, 
and water [Zedeck 1980]. Diesel exhaust contains significant amounts of 
PAHs. 
Benzo(a)pyrene, a potent carcinogen, is commonly used as an 
environmental indicator for PAHs. 
Industrial Use PAHs are found in industries that produce or use coal tar, coke, or 
bitumen (asphalt). Coal tar pitch and creosote, which are complex 
mixtures of liquid and solid aromatic hydrocarbons produced in coke 
ovens, contain significant amounts of benzo(a)pyrene and other PAHs. 
PAHs are produced in 
• coal gasification plants, 
• municipal incinerators, 
• smokehouses, and 
• some aluminum production facilities. 
Environmental 
Fate 
Once emitted to the atmosphere, weight influences the fate of the 
gaseous PAH mixtures. Heavier PAHs (more than four rings) tend to 
adsorb to particulate matter, while lighter PAHs (less than four rings) 
tend to remain gaseous until removed via precipitation [Skupinska et al. 
2004]. PAH concentrations in water tend to be low (around 100 ng/L) 
due to their weak solubility. The weak solubility leads to accumulation in 
sediments and aquatic organisms. PAHs can be absorbed by plants and 
can accumulate in soil. 
Cigarettes  Cigarette smoke contains many PAHs; therefore, cigarette smoking and 




Benzo(a)pyrene, a potent carcinogen, is generally used as an 
environmental indicator for PAHs. 
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Key Points • PAHs are ubiquitous in the environment. 
• Most PAHs in ambient air are the result of man-made processes. 
• PAHs are found in industries that produce or use coal tar, coke, or 
bitumen (asphalt). They are emitted by coal gasification plants, 
smokehouses, municipal incinerators, and some aluminum production 
facilities. 
• PAHs mostly accumulate in soils. 




3. Which of the following is true regarding PAHs? 
A. PAHs are found predominantly in water reservoirs. 
B. PAHS are found in relatively few geographic areas worldwide. 
C. PAHS are found in coal gasification plants and some aluminum 
production facilities. 
D. PAHs mostly result from natural processes. 
To review relevant content, see “Introduction” and “Industrial Use” 
in this section. 
4. Which of the following industries or processes involve PAH 
production? 
A. Smokehouses. 
B. Municipal incinerators. 
C. Coal tar or coke production or use. 
D. All of the above. 
To review relevant content, see “Industrial Use” in this section. 
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Answers 3. The correct answer is C. PAHs are found in coal gasification plants 
and some aluminum production facilities. 
4. The correct answer is D. Industries or processes that involve PAH 
production include smokehouses, municipal incinerators, and coal tar 
or coke production or use. 
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What Are the Routes of Exposure for Polycyclic Aromatic Hydrocarbons (PAHs)? 
Learning 
Objective 
Upon completion of this section, you will be able to 
• identify routes of exposure to PAHs. 
Introduction PAH exposure through air, water, soil, and food sources occurs on a 
regular basis for most people. Routes of exposure include ingestion, 
inhalation, and dermal contact in both occupational and non-occupational 
settings. Some exposures may involve more than one route 
simultaneously, affecting the total absorbed dose (such as dermal and 
inhalation exposures from contaminated air). All non-workplace sources 
of exposure such as diet, smoking, and burning of coal and wood should 
be taken into consideration. 
Air PAH concentrations in air can vary from less than 5 to 200,000 
nanograms/cubic meter (ng/m3) [Cherng et al. 1996; Georgiadis and 
Kyrtopoulos 1999]. 
Although environmental air levels are lower than those associated with 
specific occupational exposures, they are of public health concern when 
spread over large urban populations [Zmirou et al. 2000]. 
The background levels of seventeen of the Agency for Toxic Substances 
and Disease Registry’s toxicological profile priority PAHs in ambient air 
are reported to be 0.02–1.2 nanograms/m3 in rural areas and 0.15–19.3 
ng/m3 in urban areas [ATSDR 1995]. 
Cigarette smoking and environmental tobacco smoke are other sources 
of air exposure. Smoking one cigarette can yield an intake of 20–40 ng of 
benzo (a) pyrene [Phillips 1996; O’Neill et al. 1997]. Smoking one pack 
of unfiltered cigarettes per day yields 0.7 µg/day benzo(a)pyrene 
exposure. Smoking a pack of filtered cigarettes per day yields 0.4 µg/day 
[Sullivan and Krieger 2001]. 
Environmental tobacco smoke contains a variety of PAHs, such as 
benzo(a)pyrene, and more than 40 known or suspected human 
carcinogens. Side-stream smoke (smoke emitted from a burning 
cigarette between puffs) contains PAHs and other cytotoxic substances in 
quantities much higher than those found in mainstream smoke (exhaled 
smoke of smoker) [Jinot and Bayard 1996; Nelson 2001]. 
Water PAHs can leach from soil into water. Water contamination also occurs 
from industrial effluents and accidental spills during oil shipment at sea. 
Concentrations of benzo(a)pyrene in drinking water are generally lower 
than those in untreated water and about 100-fold lower than the U.S. 
Environmental Protection Agency’s (EPA) drinking water standard. (EPA’s 
maximum contaminant level [MCL] for benzo(a)pyrene in drinking water 
is 0.2 parts per billion [ppb].) 
Soil Soil contains measurable amounts of PAHs, primarily from airborne 
fallout. Documented levels of PAHs in soil near oil refineries have been as 
high as 200,000 micrograms per kilogram (µg/kg) of dried soil. Levels in 
soil samples obtained near cities and areas with heavy traffic were 
typically less than 2,000 µg/kg [IARC 1973]. 
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Foodstuffs In non-occupational settings, up to 70% of PAH exposure for a non-
smoking person can be associated with diet [Skupinska et al. 2004]. PAH 
concentrations in foodstuffs vary. Charring meat or barbecuing food over 
a charcoal, wood, or other type of fire greatly increases the concentration 
of PAHs. For example, the PAH level for charring meat can be as high as 
10–20 µg/kg [Phillips 1999]. Charbroiled and smoked meats and fish 
contain more PAHs than do uncooked products, with up to 2.0 µg/kg of 
benzo(a)pyrene detected in smoked fish. Tea, roasted peanuts, coffee, 
refined vegetable oil, cereals, spinach, and many other foodstuffs contain 
PAHs. Some crops, such as wheat, rye, and lentils, may synthesize PAHs 
or absorb them via water, air, or soil [Grimmer 1968; Menzie et al. 
1992; Shabad and Cohan 1972; IARC 1973]. 
Other Sources 
of Exposure 
PAHs are found in prescription and nonprescription coal tar products used 
to treat dermatologic disorders such as psoriasis and dandruff [Van 
Schooten 1996]. 
PAHs and their metabolites are excreted in breast milk, and they readily 
cross the placenta. 
Anthracene laxative use has been associated with melanosis of the colon 
and rectum [Badiali et al. 1985]. 
Background 
Exposures 
In the Third National Report on Human Exposure to Environmental 
Chemicals [CDC 2005], urinary levels of hydroxylated metabolites of 
PAHs were measured in a subsample of the National Health and Nutrition 
Examination Survey (NHANES) among participants aged 6 years and 
older during 1999–2002. Participants were selected within the specified 
age range to be a representative sample of the U.S. population. 
Measurements of the 22 metabolites reflect exposure to PAHs that 
occurred a few days prior to the urine samples being taken. 
Pyrene is commonly found in PAH mixtures, and its urinary metabolite, 
1-hydroxypyrene, has been used as an indicator of exposure to PAH 
chemicals [Becher and Bjorseth 1983; Granella and Clonfero 1993; Popp 
1997; Santella et al. 1993, CDC 2005]. The American Conference of 
Governmental Industrial Hygienists recommends measurement of 1-
hydroxypyrene in the end-of-shift, end-of-work-week urine samples as a 
biological exposure index (BEI) for assessment of exposure to mixtures 
containing PAHs [ACGIH 2005; Heikkila et al. 1995]. 
The geometric mean of urine concentrations (in nanograms/grams 
creatinine) of 1-hydroxypyrene for the U.S. population aged 6 years and 
older for survey years 1999–2000 was 74.2, and in survey years 2001–
2002 it was 46.4 [CDC 2005]. The geometric mean levels of 1-
hydroxypyrene in a NHANES 2001–2002 subsample is similar to that of 
other general populations residing in an urban setting [Goen et al. 1995; 
Chuang et al. 1999; Heudorf and Angerer 2001; Roggi et al. 1997; Yang 
et al. 2003]. Higher levels have been noted for residents of industrialized 
urban areas than in rural or suburban settings [Adonis et al. 2003; 
Kanoh et al. 1993; Kuo et al. 2004]. Many-fold higher levels can be 
found in workers from certain occupations [Jacob and Seidel 2002], 
including aluminum smelting [Alexandrie et al. 2000]; diesel engine 
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mechanics [Adonis et al. 2003; Kuusimaki et al. 2004]; taxi, bus, and 
truck drivers [Chuang et al. 2003; Hansen et al. 2004; Kuusimaki et al. 
2004]; painters [Lee et al. 2003], boilermakers [Mukherjee et al. 2004]; 
toll booth operators [Tsai et al. 2004]; traffic police [Merlo et al. 1998] 
and coke oven plant workers [Lu et al. 2002; Serdar et al. 2003; 
Siwinska et al. 2004]. Tobacco smoking leads to higher levels in smokers 
[Chuang et al. 2003; Adonis et al. 2003; Heudorf and Angerer 2001b] as 
well as in the non-smoking children of smokers [Tsai et al. 2003]. Coal 
stove exposure or consumption of broiled, fried, or grilled meat 
contribute to higher levels of 1-hydroxypyrene [Siwinska et al. 1999; 
Scheepers et al. 2002; Yang et al. 2003; [CDC 2005]. 
Key Points 
 
• PAH exposure occurs on a regular basis for most people. 
• In non-occupational settings, most PAH exposures for a non-smoking 
person can be associated with diet 
• Routes of exposure include inhalation, ingestion, and dermal 





5. In non-occupational settings, PAH exposure in a non-smoking 
individual mostly comes from which of the following? 
A. Foodstuff ingestion. 
B. Inhalation route. 
C. Dermal route. 
D. Water. 
To review relevant content, see “Foodstuffs” in this section. 
6. Exposure to PAHs may occur as a result of which of the following? 
A. Eating roasted peanuts. 
B. Eating charbroiled meats. 
C. Inhaling second hand tobacco smoke. 
D. All of the above. 
To review relevant content, see “Air” and “Foodstuffs” in this section. 
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Answers 5. The correct answer is A. In non-occupational settings, the majority 
of PAH exposure in a non-smoking individual comes from foodstuff 
ingestion. 
6. The correct answer is D.  Exposure to PAHs may occur as a result of 
eating roasted peanuts, eating charbroiled meats, or inhaling 
secondhand tobacco smoke. 
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Who Is at Risk of Exposure to Polycyclic Aromatic Hydrocarbons (PAHs)? 
Learning 
Objective 
Upon completion of this section, you will be able to 
• identify the populations at high risk for exposure to PAHs. 
Introduction Persons working with coal and coal products have a greater likelihood of 
exposure to PAHs. Awareness of historical occupational and 
environmental exposures can aid the clinician in not only assessing 
potential sources of exposure but also in recognizing those populations 





Percival Pott, an English surgeon, was the first to report a connection 
between occupational exposure and cancer. In 1775, he described an 
unusually high incidence of scrotal cancer among London chimney 
sweeps and suggested this was due to their exposure to soot and ash. 
Since then, other coal tar-related cancers have been induced in 
laboratory animals and found in humans [Kennaway 1995; Kjaerheim 
1999]. For example, the PAH benzo(a)pyrene, which was isolated from 
coal tar in the 1930s, was determined to be carcinogenic when applied to 
the skin of test animals. In 1947, the relationship between lung cancer 
and working conditions of gas industry workers and those working with 
coal tar was established [Kenneway 1995]. An increased incidence of 
cancers, particularly of the lung, was shown in epidemiologic studies of 
gas workers [Doll et al. 1965, 1972]. Several epidemiologic studies have 
shown increased cancer mortality in workers exposed to PAH mixtures. 
Exposure to other potentially carcinogenic substances often occurred in 
these studies [Lloyd 1971; Mazumdar et al. 1975; Redmond et al. 1972; 




Workers in industries or trades using or producing coal or coal products 
are at highest risk for PAH exposure. Those workers include, but are not 
limited to 
• aluminum workers, 
• asphalt workers, 
• carbon black workers, 
• chimney sweeps, 
• coal-gas workers, 
• coke oven workers, 
• fishermen (coal tar on nets), 
• graphite electrode workers, 
• machinists, 
• mechanics (auto and diesel engine), 
• printers, 
• road (pavement) workers, 
• roofers, 
• steel foundry workers, 
• tire and rubber manufacturing workers, and  
• workers exposed to creosote, such as 
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o carpenters, 
o farmers, 
o railroad workers, 
o tunnel construction workers, and  
o utility workers. 
A small increased risk of cancer in workers exposed to diesel exhaust has 
been suggested by some epidemiologic studies [Bhatia et al. 1998; 
Boffetta et al. 1988, 1990, 1997; Garshick et al. 1987, 1988; Steenland 
et al. 1990, 1992]. Exposure is almost always to mixtures that pose a 





Historically, in locations where gas for lighting and heating was 
manufactured from coal or oil, large amounts of PAHs existed and may 
still exist as waste deposits. Before World War II, more than 1,000 coal 
gasification plants are estimated to have existed throughout the 
midwestern and eastern United States [Environmental Research and 
Technology 1984]. These plants began to phase out in the early 1950s 
when the use of interstate natural gas pipelines became more prominent. 
Susceptible 
Populations 
Fetuses may be at risk for PAH exposure. PAH and its metabolites have 
been shown to cross the placenta in various animal studies [ATSDR 
1995]. 
Because PAHs are excreted in breast milk, nursing infants of exposed 
mothers can be secondarily exposed.  
Key Points • PAH and metabolites cross the placenta and are excreted in breast 
milk. 
• Occupations that entail exposure to PAH include workers exposed to 
coal and coal products.  
Progress 
Check 
7. Which of the following groups of workers is (are) at most risk of heavy 
exposure to PAHs on the job? 
A. Workers exposed to creosote. 
B. Steel foundry workers. 
C. Roofers. 
D. All of the above. 
To review relevant content, see “Current Occupational Exposures” in 
this section. 
8. Which of the following is true regarding PAH exposure? 
A. Those most at risk are workers in the auto emission testing 
industry. 
B. Health endpoints can often be directly traced to a specific PAH 
metabolite. 
C. PAHs cross the placenta. 
D. None of the above. 
To review relevant content, see “Current Occupational Exposures” and 
“Susceptible Populations” in this section. 
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Answers 7. The correct answer is D. Steel foundry workers, roofers, and workers 
exposed to creosote have jobs that put them at risk of heavy 
exposure to PAHs. 
8. 8. The correct answer is C. PAHs do cross the placenta. Persons 
working with coal and coal products have a greater likelihood of 
exposure to PAHs than workers in the auto emission testing industry. 
Exposures are typically to mixtures of PAHs, making it difficult to 
attribute a health end point to a specific PAH metabolite. 
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Upon completion of this section, you will be able to 
• describe the Occupational Safety and Health Administration’s 
(OSHA) Permissible Exposure Level (PEL) for PAH, and 
• describe the U.S. Environmental Protection Agency’s (EPA) 
Maximum Contaminant Level (MCL) for PAH in drinking water. 
Introduction  
 
U.S. government agencies have established standards that are relevant 
to PAHs exposures in the workplace and the environment. There is 
• a standard relating to PAH in the workplace, and 
• a standard for PAH in drinking water. 
Workplace OSHA has not established a substance-specific standard for occupational 
exposure to PAHs. Exposures are regulated under OSHA's Air 
Contaminants Standard  for substances termed coal tar pitch volatiles 
(CTPVs) and coke oven emissions. Employees exposed to CTPVs in the 
coke oven industry are covered by the coke oven emissions standard. 
The OSHA coke oven emissions standard requires employers to control 
employee exposure to coke oven emissions by the use of engineering 
controls and work practices. Wherever the engineering and work practice 
controls that can be instituted are not sufficient to reduce employee 
exposures to or below the permissible exposure limit, the employer shall 
nonetheless use them to reduce exposures to the lowest level achievable 
by these controls and shall supplement them by the use of respiratory 
protection. The OSHA standard also includes elements of medical 
surveillance for workers exposed to coke oven emissions. 
Air 
The OSHA PEL for PAHs in the workplace is 0.2 milligram/cubic meter 
(mg/m3). 
The OSHA-mandated PAH workroom air standard is an 8–hour time-
weighted average (TWA) permissible exposure limit (PEL) of 0.2 mg/m3, 
measured as the benzene-soluble fraction of coal tar pitch volatiles. The 
OSHA standard for coke oven emissions is 0.15 mg/m3. The National 
Institute for Occupational Safety and Health (NIOSH) has recommended 
that the workplace exposure limit for PAHs be set at the lowest 
detectable concentration, which was 0.1 mg/m3 for coal tar pitch volatile 
agents at the time of the recommendation. Table 1 summarizes relevant 
exposure criteria for PAHs. 
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Table 1. Standards and Regulations for Polycyclic Aromatic Hydrocarbons (PAHs) 









0.2 milligrams per cubic 
meter (mg/m3) for 
benzene-soluble coal tar 
pitch fraction 









0.1 mg/m3 for coal tar 
pitch volatile agents 
 








0.2 mg/m3 for benzene-
soluble coal tar pitch 
fraction 
 
Regulation: (benzene soluble 
fraction of coal tar volatiles) 
PEL§ (8-hour workday) 
0.0001 milligrams per 
liter (mg/L) 
MCL¶ for benz(a)anthracene 
0.0002 mg/L 
 












0.0004 mg/L MCL for indenol(1,2,3-
c,d)pyrene 
*TLV: threshold limit value. 
†TWA (time-weighted average): concentration for a normal 8-hour workday and a 40-hour 
workweek to which nearly all workers may be repeatedly exposed. 
‡REL (recommended exposure limit): recommended airborne exposure limit for coal tar 
pitch volatiles (cyclohexane-extractable fraction) averaged over a 10-hour work shift. 
§PEL (permissible exposure limit): the legal airborne permissible exposure limit (PEL) for 
coal tar pitch volatiles (benzene soluble fraction) averaged over an 8-hour work shift. 
¶MCL: maximum contaminant level. 
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Standards The maximum contaminant level goal for benzo(a)pyrene in drinking 
water is 0.2 parts per billion (ppb). 
In 1980, EPA developed ambient water quality criteria to protect human 
health from the carcinogenic effects of PAH exposure. The 
recommendation was a goal of zero (nondetectable level for carcinogenic 
PAHs in ambient water). EPA, as a regulatory agency, sets a maximum 
contaminant level (MCL) for benzo(a)pyrene, the most carcinogenic PAH, 
at 0.2 ppb. EPA also sets MCLs for five other carcinogenic PAHs (see 
Table 1). 
For more information on EPA rules and regulations regarding PAH, visit 
EPA’s Web site at www.epa.gov. 
Food 
The U.S. Food and Drug Administration has not established standards 
governing the PAH content of foodstuffs. 
Key Points • OSHA’s PEL for PAH in the workplace is 0.2 mg/m
3 for benzene-
soluble coal tar pitch fraction of air (8-hour TWA). 
• OSHA requires workers to be trained in the proper use of appropriate 
personal protective equipment (PPE) and safety.  
• Workers must receive medical surveillance if exposed above the PEL.  
• EPA’s maximum contaminant level (MCL) for PAH in drinking water is 
0.2 ppb of drinking water. 
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9. Which of the following is true regarding OSHA’s role in PAH exposure 
limits? 
A. OSHA is a regulatory agency that has a permissible exposure level 
(PEL) established for PAHs in the workplace. 
B. OSHA requires all workers to be provided with appropriate 
personal protection equipment (PPE) and receive safety training. 
C. OSHA requires workers to receive medical surveillance if exposed 
above the permissible exposure limit PEL. 
D. All of the above. 
To review relevant content, see “Workplace Standards” in this 
section. 
10. Which of the following is true regarding EPA’s role in PAH exposure 
limits? 
A. The maximum contaminant levels (MCLs) for PAHs are set to 
protect human health against the carcinogenic effects of PAH. 
B. EPA regulates PAH levels in foodstuffs. 
C. EPA is a regulatory agency that has established MCLs for several 
PAHs in air. 
D. MCLs are based on an 8–hour time weighted average. 
To review relevant content, see “Environmental Standards” in this 
section. 
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Answers 9. The correct answer is D. OSHA is a regulatory agency which has 
established a PEL established for PAHs in the workplace. OSHA 
requires all workers to be provided with appropriate PPE and receive 
safety training. OSHA requires workers to receive medical 
surveillance if exposed above the PEL. 
10. The correct answer is A. The MCLs for PAHs are set to protect 
human health against the carcinogenic effects of PAHs. The FDA, not 
EPA, regulates contaminant levels in foodstuffs and currently has no 
standard set for PAHs in foodstuffs. EPA is a regulatory agency that 
has established MCLs for several PAHs in water, not air. OSHA’s 
PELs are based on an 8–hour time-weighted average, not EPA’s 
MCLs. 
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What Is the Biologic Fate of PAHs in the Body? 
Learning 
Objective 
Upon completion of this section, you will be able to 
• describe the biologic fate of the PAHs in the body. 
Introduction 
 
Once PAHs enter the body, several things occur: 
• PAHs are metabolized in a number of organs and excreted in bile 
and urine 
• PAHs are excreted in breast milk and stored to a limited degree in 
adipose tissue. 
Not much data for humans exists regarding the metabolic fate of PAHs. 
However, information on absorption, distribution, and elimination of 
these substances is available from animal studies.  
Pyrene is commonly found in PAH mixtures, and its urinary metabolite, 1-
hydroxypyrene, has been used as an indicator of exposure to PAH 
chemicals [Becher and Bjorseth 1983; Granella and Clonfero 1993; Popp 
1997; Santella et al. 1993, CDC 2005]. The ACGIH recommends 
measurement of 1-hydroxypyrene in the end-of-shift, end-of-work-week 
urine samples as a biological exposure index (BEI) for assessment of 
exposure to mixtures containing PAHs. 
Measurements of 22 PAH hydroxylated urinary metabolites were taken as 
part of the Third National Report on Human Exposure to Environmental 
Chemicals from a subsample of the National Health and Nutrition 
Examination Survey (NHANES) from participants aged 6 years and older 
during 1999–2002. These data provide physicians with a reference range 
so that they can determine whether people have been exposed to higher 
levels of PAHs than are found in the general population [CDC 2005]. 
Absorption PAHs are absorbed through ingestion, inhalation, and dermal contact, 
according to animal study data. The percent absorbed varies in these 
studies for several reasons, including the vehicle (transport medium) in 
which the PAHs are found [Kawamura et al. 1988]. In general, PAHs not 
bound to particulate matter may be absorbed in the lungs better than the 
same dose found on the surface of airborne particulate matter [Cresia et 
al. 1976; Seto 1993]. 
Distribution Once absorbed, PAHs 
• enter the lymph, 
• circulate in the blood, and 
• are metabolized primarily in the liver and kidney. 
PAHs differ with respect to distribution patterns and lipophilic properties 
[Busbee et al. 1990]. Because of their lipophilic nature, PAHs can 
accumulate in breast milk and adipose tissue. However, biliary and 
urinary excretion of PAHs is relatively efficient because of the wide 
distribution of enzymes that transform PAHs into polar metabolites. 
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Metabolism 
and Excretion 
PAHs are predominantly metabolized via CYP enzymes (enzymes in the 
P-450 mixed-function oxidase system) in the liver [Kapitulnik et al. 1977; 
Keifer et al. 1988; Monteith et al. 1987]. 
In addition to the liver and kidneys, metabolism of PAHs occurs in the 
adrenal glands, testes, thyroid, lungs, skin, sebaceous glands, and small 
intestines [ATSDR 1995]. 
PAHs are transformed initially to epoxides, which are converted to 
dihydrodiol derivatives and phenols. Glucuronide and sulfate conjugates 
of these metabolites are excreted in the bile and urine. Glutathione 
conjugates are further metabolized to mercapturic acids in the kidney 
and are excreted in the urine. 
The hydroxylated metabolites of the PAHs are excreted in human urine 
both as free hydroxylated metabolites and as hydroxylated metabolites 
conjugated to glucuronic acid and sulfate [CDC 2005]. A commonly 
measured urinary metabolite is 1-hydroxypyrene [Becher and Bjorseth 
1983; Granella and Clonfero 1993; Popp 1997; Santella 1993]. 
Metabolism is a prerequisite for hepatobiliary excretion and elimination 
through the feces, regardless of route of entry. 
Excretion half-lives in feces and urine have been reported in animal 
studies as 22 hours and 28 hours, respectively [Becher and Bjorseth 
1983]. 
Key Points • Absorption by route varies in animal studies. 
• PAH distribution patterns vary due to differences in lipophilic 
properties. 
• Metabolism via CYP liver enzymes (enzymes in the P-450 mixed-
function oxidase system) is the predominant mechanism of PAH 
metabolism. 
• PAHs are transformed to epoxides, then to dihydrodiol derivatives and 
phenols. 
• Excretion occurs via the bile or urine after metabolite conjugation to 
glucuronides and sulfates.  
• 1- Hydroxypyrene is a commonly measured urine metabolite. 
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11. Which of the following is true regarding PAHs? 
A. PAHs are mostly excreted unchanged in the feces. 
B. PAHs are stored in adipose tissue to a large extent. 
C. PAHs have varied distribution patterns. 
D. PAHs become lodged and are retained in lung tissue. 
To review relevant content, see “Absorption”, “Distribution”, and 
“Metabolism and Excretion” in this section. 
12. Which of the following is true of PAHs? 
A. All PAH metabolites are formed via CYP liver enzymes (enzymes in 
the P-450 mixed function oxidase system). 
B. PAHs can accumulate in breast milk and adipose tissue. 
C. Most PAHs have similar distribution patterns and lipophilic 
properties. 
D. PAHs bound to particulate matter are better absorbed in the lungs 
than are unbound PAHs. 
To review relevant content, see “Absorption”, “Distribution”, and 
“Metabolism and Excretion” in this section. 
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Answers 11. The correct answer is C. PAHs have varied distribution patterns due 
to differences in lipophilic properties. Because of their lipophilic 
nature, PAHs can accumulate in breast milk and adipose tissue. 
However, biliary and urinary excretion of PAHs is relatively efficient 
because of the wide distribution of enzymes that transform PAHs 
into polar metabolites. 
12. The correct answer is B. PAHs can accumulate in breast milk and 
adipose tissue. Not all PAH metabolites are formed via CYP liver 
enzymes (enzymes in the P-450 mixed function oxidase system). 
PAHs do differ in their distribution patterns and lipophilic properties. 
Unbound PAHs are better absorbed in the lungs, not bound PAHs.  
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How Do PAHs Induce Pathogenic Change? 
Learning 
Objective 
Upon completion of this section, you will be able to 
• describe how PAHs are believed to induce pathogenic changes. 
Introduction A key factor in PAH toxicity is the formation of reactive metabolites. Not 
all PAHs are of the same toxicity because of differences in structure that 
affect metabolism. 
Another factor to consider is the biologic effective dose, or the amount 
of toxics that actually reaches the cells or target sites where interaction 
and adverse effects can occur. 
CYP1A1, the primary cytochrome P-450 isoenzyme that biologically 
activates benzo (a) pyrene, may be induced by other substances 
[Kemena et al. 1988; Robinson et al. 1975]. 
The mechanism of PAH-induced carcinogenesis is believed to be via the 
binding of PAH metabolites to deoxyribonucleic acid (DNA). 
Carcinogenicity Some parent PAHs are weak carcinogens that require metabolism to 
become more potent carcinogens. Diol epoxides—PAH intermediate 
metabolites—are mutagenic and affect normal cell replication when they 
react with DNA to form adducts. A theory to explain the variability in 
the potency of different diol epoxides, “the bay theory,” predicts that an 
epoxide will be highly reactive and mutagenic if it is in the “bay” region 
of the PAH molecule (Figure 1) [Jerina et al. 1976 and 1980; Weis 
1998]. The bay region is the space between the aromatic rings of the 
PAH molecule. 
PAH-induced carcinogenesis can result when a PAH-DNA adduct forms 
at a site critical to the regulation of cell differentiation or growth. A 
mutation occurs during cell replication if the aberration remains 
unrepaired. Cells affected most significantly by acute PAH exposure 
appear to be those with rapid replicative turnover, such as those in 
bone marrow, skin, and lung tissue. Tissues with slower turnover rates, 
such as liver tissue, are less susceptible. 
Benzo(a)pyrene diol epoxide adducts bind covalently to several guanine 
positions of the bronchial epithelial cell DNA p53 gene, where cancer 
mutations are known to occur from exposure to cigarette smoke. This is 





CYP1A1 inducible persons might be at greater risk for the effects of 
PAHs. 
Persons with a high degree of CYP1A1 inducibility may be more 
susceptible to PAH health risks. Genetic variation in CYP1A1 inducibility 
has been implicated as a determining factor for susceptibility to lung 
and laryngeal cancer. 
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CYP1A1, the primary cytochrome P-450 isoenzyme that biologically 
activates benzo (a) pyrene, may be induced by other substances 
[Kemena et al. 1988; Robinson et al. 1975]. 
Glutathione transferase deficiencies may result in elevated cancer risk. 
Several studies have focused on breast cancer risk and metabolism of 
PAHs [Ambrosone et al. 1995; Calaf and Russo 1993; Davis et al. 1993; 
Hecht et al. 1994]. 
Oncogene 
Activation 
Several animal studies have implicated the ras oncogene in PAH tumor 
induction [Chakravarti et al. 1995; DiGiovanni et al. 1993; Ronai et al. 
1994]. 
Key Points • The formation of reactive metabolites and the biologically effective 
dose are key to PAH toxicity. 
• Diol epoxides—PAH intermediate metabolites—are mutagenic and 
affect normal cell replication when they react with DNA to form 
adducts. 
• The location of epoxides in the bay region of a PAH predicts 
reactivity and mutagenicity. 
• DNA adducts, as markers of exposure used in research, can be 
measured in various biologic media.  
• The ability of CYP1A1 to biologically activate PAHs may be heritable 
and thus point to genetically susceptible populations at risk of PAH 
carcinogenesis. 
Progress Check 13. The mechanism of PAH-induced carcinogenesis is believed to be 
which of the following? 
A. Binding of PAH metabolites to DNA. 
B. Generation of active oxygen species. 
C. Cell-mediated inflammatory mechanisms. 
D. All of the above. 
To review relevant content, see “Carcinogenicity” in this section. 
14. Which of the following is (are) true regarding PAHs? 
A. Tissues with rapid cell turnover are most vulnerable to the 
carcinogenic effects from some PAHs. 
B. The degree to which CYP1A1 biologically activates PAHs may be 
heritable. 
C. The location of epoxides in the bay region of a PAH predicts 
reactivity and mutagenicity. 
D. All of the above are true. 
To review relevant content, see “Carcinogenicity” and “Genetic 
Susceptibility” in this section. 
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Answers 13. The correct answer is A. The mechanism of PAH induced 
carcinogenesis is believed to be the binding of PAH metabolites to 
DNA. 
14. The correct answer is D. All of the statements are true. Tissues 
with rapid cell turnover are most vulnerable to the carcinogenic 
effects from some PAHs; the degree to which CYP1A1 biologically 
activates PAHs may be heritable; and the location of epoxides in 
the bay region of a PAH predicts reactivity and mutagenicity. 
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What Health Effects Are Associated With PAH Exposure? 
Learning 
Objective 
Upon completion of this section, you will be able to 
• describe health effects associated with PAH exposure. 
Introduction The most significant endpoint of PAH toxicity is cancer. 
PAHs generally have a low degree of acute toxicity to humans. Some 
studies have shown noncarcinogenic effects that are based on PAH 
exposure dose [Gupta et al. 1991]. 




• renal, and dermatologic systems.  
Many PAHs are only slightly mutagenic or even nonmutagenic in vitro; 
however, their metabolites or derivatives can be potent mutagens. 
Carcinogenicity The carcinogenicity of certain PAHs is well established in laboratory 
animals. Researchers have reported increased incidences of skin, lung, 
bladder, liver, and stomach cancers, as well as injection-site sarcomas, 
in animals. Animal studies show that certain PAHs also can affect the 
hematopoietic and immune systems and can produce reproductive, 
neurologic, and developmental effects [Blanton 1986, 1988; Dasgupta 
and Lahiri 1992; Hahon and Booth 1986; Malmgren et al. 1952; Philips 
et al. 1973; Szczeklik et al. 1994; Yasuhira 1964; Zhao 1990]. 
It is difficult to ascribe observed health effects in epidemiological 
studies to specific PAHs because most exposures are to PAH mixtures. 
Increased incidences of lung, skin, and bladder cancers are associated 
with occupational exposure to PAHs. Epidemiologic reports of PAH-
exposed workers have noted increased incidences of skin, lung, bladder, 
and gastrointestinal cancers. These reports, however, provide only 
qualitative evidence of the carcinogenic potential of PAHs in humans 
because of the presence of multiple PAH compounds and other 
suspected carcinogens. Some of these reports also indicate the lack of 
quantitative monitoring data [Hammond et al. 1976; Lloyd 1971; 
Mazumdar 1975; Redmond et al. 1972; Redmond and Strobino 1976]. 
The earliest human PAH-related epidemiologic study was reported in 
1936 by investigators in Japan and England who studied lung cancer 
mortality among workers in coal carbonization and gasification 
processes. Subsequent U.S. studies among coke oven workers 
confirmed an excess of lung cancer mortality, with the suggestion of 
excessive genitourinary system cancer mortality. Later experimental 
studies showed that PAHs in soot were probably responsible for the 
increased incidence of scrotal cancer noted by Percival Pott among 
London chimney sweeps in his 1775 treatise [Zedeck 1980]. 
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Research Continued research regarding the mutagenic and carcinogenic effects 
from chronic exposure to PAHs and metabolites is needed. The following 
table indicates the carcinogenic classifications of selected PAHs by 
specific agencies. 
 
Agency PAH Compound(s) 
Carcinogenic 
Classification 
U.S. Department of 











for Research on 
Cancer (IARC) 






 • benzo(a)fluoranthene, 












• phenanthrene, and 
• pyrene. 
Not classifiable as to 





















• phenanthrene, and pyrene. 
Not classifiable as to 
human carcinogenicity 
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Key Points • PAHs generally have a low degree of acute toxicity to humans. 
• The most significant endpoint of PAH toxicity is cancer. 
• Increased incidences of lung, skin, and bladder cancers are 
associated with occupational exposure to PAHs. Data for other 
sites is much less persuasive. 
• It is difficult to ascribe observed health effects in epidemiological 
studies to specific PAHs because most exposures are to PAH 
mixtures. 
• Animal studies show that certain PAHs affect the hematopoietic, 
immune, reproductive, and neurologic systems and cause 
developmental effects. 
Progress Check 15. Which of the following is (are) true? 
A. PAHs generally have a high degree of acute toxicity in humans. 
B. PAHs have been associated with increased incidences of lung, 
skin, and bladder cancers from occupational exposures. 
C. Specific PAHs can easily be linked to observed health effects in 
epidemiologic studies. 
D. All of the above. 
To review relevant content, see “Introduction” and “Carcinogenicity” 
in this section. 
16. According to IARC and EPA, which of the following PAHs are 




D. Both A and B. 
To review relevant content, see “Carcinogenicity” in this section. 
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Answers 15. The correct answer is B. PAHs have been associated with increased 
incidences of lung, skin, and bladder cancers from occupational 
exposures. PAHs, however, do not have a high degree of acute 
toxicity in humans. It also is difficult to ascribe observed health 
effects in epidemiological studies to specific PAHs because most 
exposures are to PAH mixtures. 
16. The correct answer is D. According to IARC and EPA, both 
benzo(a)pyrene and benz(a)anthracene are probable human 
carcinogens. Anthracene is not classifiable as to its carcinogenicity 
to humans by either agency. 
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Upon completion of this section, you will be able to 
• describe typical signs and symptoms of patients with acute PAH 
exposure, 
• describe typical signs and symptoms of patients with chronic PAH 
exposure, 
• describe important elements of the exposure history, 
• describe the focus of the physical examination, and 
• describe tests used to assist in evaluation of patients exposed to 
PAHs. 
Introduction In addition to the standard clinical approaches to patient evaluation, 
clinicians should take an appropriate PAH exposure history. They should 







Acute effects attributed to PAH exposure, such as headache, nausea, 
respiratory and dermal irritation, are probably caused by other agents. 
Since PAHs have low acute toxicity, other more acutely toxic agents 
probably cause the acute symptoms attributed to PAHs. Hydrogen sulfide 
in roofing tars and sulfur dioxide in foundries are examples of 
concomitant, acutely toxic contaminants. Naphthalene, the most 
abundant constituent of coal tar, is a skin irritant, and its vapors may 






Effects reported from occupational exposure to PAHs include 
• chronic bronchitis, 
• chronic cough irritation, 
• bronchogenic cancer, 
• dermatitis, 
• cutaneous photosensitization, and 
• pilosebaceous reactions. 
Reported health effects associated with chronic exposure to coal tar and 
its by-products (e.g., PAHs). 
• Skin: erythema, burns, and warts on sun-exposed areas with 
progression to cancer. The toxic effects of coal tar are enhanced by 
exposure to ultraviolet light. 
• Eyes: irritation and photosensitivity. 
• Respiratory system: cough, bronchitis, and bronchogenic cancer. 
• Gastrointestinal system: leukoplakia, buccal-pharyngeal cancer, 
and cancer of the lip. 
• Hematopoietic system: leukemia (inconclusive) and lymphoma. 
• Genitourinary system: hematuria and kidney and bladder cancers. 
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Exposure is most often determined based on the patient exposure 
history. 
A relevant patient history might include the following information: 
• occupational history, 
• occupation of the spouse and other household members, 
• use of medications, including coal tar-containing dermatologic 
preparations, 
• diet, especially charbroiled meats, 
• alcohol consumption; and 
• smoking habits. 
Hobbies and recreational activities might reveal additional evidence of 
exposure to PAH-containing mixtures.  
In general, risk increases with total dose. 
For more information on the exposure history, see the Taking an 




Physical examination is important. 
Physical examination should include a review of all systems, with the 
knowledge that cancer is the most significant endpoint of chronic PAH 
toxicity. If PAH exposure is suspected, the clinician should be alert to 
malignant transformation of actinic skin lesions. The buccal mucosa and 
oropharynx should be inspected for malignant changes. Inspection of 
sun-exposed areas for evidence of hyperpigmentation in response to 





Direct biologic measurement of PAHs is neither cost-effective nor 
clinically useful. Direct measurement refers to testing directly for the 
parent compound (or specific PAHs exposed to), not the metabolites. 
Although researchers have examined PAHs directly in the blood and 
tissues of experimental animals, these methods have not been widely 
used for human samples. The high costs of testing and limited knowledge 
of the significance of background levels in humans limit the clinical 




The most common tests for determining exposure to PAHs involve 
examining tissues, blood, and urine for the presence of metabolites. 
Pyrene is commonly found in PAH mixtures, and its urinary metabolite, 1-
hydroxypyrene, has been used as an indicator of exposure to PAH 
chemicals [Becher and Bjorseth 1983; Granella and Clonfero 1993; Popp 
1997; Santella et al. 1993, CDC 2005]. The ACGIH recommends 
measurement of 1-hydroxypyrene in the end-of-shift, end-of-work-week 
urine samples as a biological exposure index (BEI) for assessment of 
exposure to mixtures containing PAHs. This practice may help identify 
workplaces requiring improved industrial hygiene measures [ACGIH 
Page 39 of 68 
Agency for Toxic Substances and Disease Registry (ATSDR) 
Case Studies in Environmental Medicine 
Toxicity  of Polycyclic Aromatic Hydrocarbons (PAHs)  
2005; Heikkila et al. 1995]. 
In the Third National Report on Human Exposure to Environmental 
Chemicals, urinary levels of hydroxylated metabolites of PAHs were 
measured in a subsample of the National Health and Nutrition 
Examination Survey (NHANES) participants aged 6 years and older 
during 1999–2002. The geometric mean for 1-hydroxypyrene (ng/g of 
creatinine) for the U.S. population aged 6 years and older during 1999–
2002 was 74.2, with a 95% confidence interval of (61.6–89.3). 
Note that finding a measurable amount of one or more metabolites in the 
urine does not mean that the levels of the PAH metabolites cause an 
adverse health effect. Whether levels of PAH metabolites at the levels 
reported are cause for health concern is not known, and more research is 
needed. These data provide physicians with a reference range so that 
they can determine whether people have been exposed to higher levels 
of PAHs than are found in the general population. As well, the data help 
scientists plan and conduct research on exposure to PAHs and health 
effects. 
Deoxyribonucleic acid (DNA) adducts may be used as an indicator of 
exposure in research settings and can be measured in a variety of 
biologic media [Popp 1997; Ross et al. 1991; Santella et al. 1993; 
Weyand and La Voie 1988]. For example, tissue in culture can be labeled 
with radioactive phosphorus and analyzed by thin-layer chromatography 
and scintillation to identify and quantify the DNA adducts formed. Also, 
an immunoassay technique, ELISA, has been developed to detect 
antibodies to the PAH-DNA adducts in blood. These tests are not readily 
available for routine clinical use. 
PAH diol epoxides form adducts with hemoglobin in the red blood cells. 
These adducts can be quantified by use of fluorescence spectroscopy. 
This technique is limited in its potential usefulness, however, because of 
individual differences in PAH metabolism and the limited specificity of the 
technique itself. 
In general, indirect biologic monitoring can be useful in determining 
whether exposure to PAHs has occurred. However, it is not clinically 
useful for evaluating individual patients because normal or toxic levels 
have not been determined. Arterial blood gases, a chest radiograph, and 
other monitoring might be indicated. Individual variability, confounding 
effects of drugs or cigarettes, and nonspecificity of techniques are likely 
to complicate the interpretation of the results, especially in low-level 
environmental exposures. 
Employees exposed to CTPVs in the coke oven industry are covered by 
the coke oven emissions standard. This OSHA standard includes elements 
of medical surveillance for workers exposed to coke oven emissions. It 
should be noted that OSHA recommended surveillance set at the time of 
the standard might not necessarily be consistent with current evidenced 
based medical practice. 
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Key Points • Acute effects attributed to PAH exposure are probably caused by 
other agents. 
• Exposure is most often determined based on the patient exposure 
history. 
• Pertinent exposure history should include past and current 
occupational, recreational, hobbies, dietary, and smoking 
assessments. 
• Physical examination is important, including a review of all systems. 
• Direct biologic measurement of PAHs is neither cost-effective nor 
clinically useful. 
• A commonly measured urinary metabolite used to assess PAH 
exposure is 1-hydroxypyrene. 
• DNA adducts may be used as an indicator of exposure in research 
settings and can be measured in a variety of biologic media. 
Progress 
Check 
17. Which of the following is (are) true regarding the evaluation of a 
patient exposed to PAHs? 
A. Urinary 1-hydroxypyrene levels are used as prognostic indicators. 
B. Direct biologic measurement of PAHs is clinically useful. 
C. Exposure is most often determined based on the patient exposure 
history. 
D. All of the above. 
To review relevant content, see “Exposure History”, “Direct Biological 
Measurement” and “Indirect Biological Measurement” in this section. 
18. Key features of the physical examination of PAH-exposed patients 
include which of the following? 
A. Inspection of the buccal mucosa and oropharynx. 
B. Inspection of skin, especially sun-exposed areas. 
C. Auscultation of the lungs. 
D. All of the above. 
To review relevant content, see “Physical Examination” in this section. 
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Answers 17. The correct answer is C. Exposure is most often determined based 
on the patient exposure history. Urinary 1-hydroxypyrene levels are 
used as exposure indicators, not prognostic indicators. Direct 
biologic measurement of PAHs is not clinically useful. 
18. The correct answer is D. Physical examination of PAH-exposed 
patients includes a complete review of systems for carcinogenic 
endpoints, which includes the inspection of the buccal mucosa and 
oropharynx, inspection of skin (especially sun-exposed areas), and 
auscultation of the lungs. 
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How Should Patients Exposed to PAHs Be Treated and Managed? 
Learning 
Objectives 
Upon completion of this section, you will be able to  
• identify strategies for managing patients with acute high dose 
PAH exposure, and 




The management and treatment focus of individuals exposed to PAHs 
differs for high dose acute and low dose chronic exposures. 
Decontamination and supportive measures are the primary objectives 
after acute high dose PAH exposure. Treatment of chronic PAH toxicity 
is symptomatic and supportive. Health education and risk 
communication are important aspects of patient care. Some clinicians 
recommend periodic pulmonary function tests and chest x-rays for PAH-
exposed individuals (inhalation exposures).  
Acute High 
Dose Exposure 
Decontamination and supportive measures are the primary objectives 
after acute high dose PAH exposure. Acute symptoms are generally 
from co-exposures to other substances. 
Contaminated clothing should be removed from the victim as soon as 
possible. The victim’s skin should be decontaminated by gently 
scrubbing with soap and water. Ocular contamination should be treated 
with irrigation and a complete eye examination. Supportive care should 




Effective risk communication and education for patients at risk for PAH-
related disease is an important part of patient care. Persons exposed to 
potentially significant levels of PAHs should be aware of the increased 
risk for bronchogenic cancer and the additive effect of cigarette smoke 
and other toxic agents. Periodic evaluations of healthy patients who 
have been significantly exposed to PAHs, even in the absence of 
symptoms, may facilitate early diagnosis and intervention if a 
malignancy develops.  
The OSHA coke oven emissions standard includes elements of medical 
surveillance for workers exposed to coke oven emissions. It should be 
noted that OSHA recommended surveillance (set at the time of the 
standard) might not necessarily be consistent with current evidenced 
based medical practice. 
Risk 
Communication 
in Patient Care 
Because estimation of additional risk due to PAH exposure is often 
impossible, the challenge to the clinician is to maintain a balance 
between appropriate concern and undue alarm. 
Predicting the carcinogenicity of a complex chemical mixture based on 
one or several of its components is difficult because of possible 
interactions among the components. 
Effective risk communication takes this into account and can be 
important in prevention or management of disease. 
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Key Points • Decontamination and supportive measures are the primary 
objectives after acute high dose PAH exposure.  
• Treatment of chronic PAH toxicity is generally symptomatic and 
supportive. 
• Effective risk communication and health education are important 
aspects of patient care.  
• Periodic evaluations of healthy patients who have been significantly 
exposed to PAHs, even in the absence of symptoms, is 
recommended by some clinicians to facilitate early diagnosis and 
intervention if a malignancy develops. 
Progress Check 19. Primary strategies for managing patients with acute high dose 
exposure to PAH include(s) which of the following? 
A. Removal of contaminated clothing. 
B. Cleansing of skin with soap and water. 
C. Supportive care as clinically indicated. 
D. All of the above. 
To review relevant content, see “Acute High Dose Exposure” in this 
section.  
20. When managing patients with chronic low-level exposure to PAH, 
strategies aimed at reducing patient risk of overexposure to PAHs 
and PAH related disease include (s) which of the following? 
A. Smoking cessation. 
B. Patient health education. 
C. Periodic evaluations for those significantly exposed. 
D. All of the above. 
To review relevant content, see “Risk Communication in Patient 
Care” in this section. 
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Answers 19. The correct answer is D. Since symptoms from acute PAH 
exposures are mainly from co-exposure to other substances, the 
primary strategies for managing patients with acute high dose 
exposure to PAH include removal of contaminated clothing, 
decontamination of skin with soap and water, and supportive care 
as clinically indicated. 
20. The correct answer is D. When managing patients with chronic low 
level exposure to PAH, strategies aimed at reducing patient risk of 
overexposure to PAHs and PAH related disease include smoking 
cessation, patient health education, and periodic evaluations for 
those significantly exposed. 
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What Instructions Should Be Given to Patients to Prevent Overexposure to PAHs? 
Learning 
Objective 
Upon completion of this section, you will be able to 
• describe care advice the clinician can provide to patients to prevent 
overexposure to PAHs. 
Introduction 
 
By utilizing effective risk communication techniques, the clinician can 
promote patient behaviors that may reduce the risk of PAH overexposure 
and PAH related disease. The clinician can provide advice on 
• self-care, so that patients can minimize risk of PAH overexposure 
and 
• when to follow-up with a health care provider. 
ATSDR has developed patient education care instruction sheets for use in 




Self-care advice creates awareness and suggests actionable behaviors 
that may reduce the risk of PAH overexposure and PAH related disease. 
 
Sample Advice Rationale 
Stop smoking and avoid 
exposure to smoke. 
Smoking and exposure to second hand smoke increase the risk 
of lung cancer. 
Cigarette smoke contains PAHs and other carcinogenic 
substances. Exposure to PAHs by smoking or second hand smoke 
may increase the risk of overexposure to PAHs and PAH related 
disease. 
Minimize dietary PAH 
exposures. 
The FDA has not published PAH “safe levels” for foodstuffs. 
However, given that PAHs in food increase the exposure dose 
and risk of adverse health effects, efforts to minimize dietary 
contributions would be prudent. 
Foods that may contain PAHs include 
• charbroiled, chargrilled, and smoked meats and fish, 
• tea, 
• roasted peanuts, 
• coffee, 




• rye, and 
• lentils. 
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Awareness of potential PAH exposure through hobbies, 
recreational, and home/outdoor scenarios and taking action to 
minimize or avoid exposure may decrease the risk of PAH 
overexposure. 
Wearing gloves when working with cutting oils (as well as other 
PAH-containing substances encountered in hobbies, recreational, 
and home/outdoor scenarios) and avoiding outdoor burning 
practices are some examples of behaviors that would decrease 




Follow up with 
a Health Care 
Provider 
Patients should be advised to consult their physician if they develop signs 
or symptoms to include 
• a new cough or chronic cough with or without hemoptysis, 
• unexplained weight loss, 
• shortness of breath, and 
• other applicable health changes associated with cancer or other 
serious health condition such as increased fatigue and weakness, 
recurring respiratory infections, etc. 
Key Points • The clinician can promote patient behaviors that may reduce the 
risk of PAH overexposure and PAH related disease by providing 
advice on 
o self-care, so that patients can minimize risk of PAH 
overexposure and 
o when to follow-up with a health care provider. 
Progress 
Check 
21. Clinicians can help their patients reduce the risk of overexposure to 
PAHs and PAH related disease by 
A. Offering information and assistance with smoking cessation. 
B. Providing information on PAH related health effects. 
C. Providing information on behaviors that can reduce the risk of 
PAH overexposure and PAH related disease. 
D. All of the above. 
To review relevant content, see “Self Care Advice” in this section. 
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Answers 21. The correct answer is D. Clinicians can help their patients reduce the 
risk of overexposure to PAHs and PAH related disease by offering 
information and assistance with smoking cessation, providing 
information on PAH related health effects, and providing information 
on behaviors that can reduce the risk of PAH overexposure and PAH 
related disease. 
 
Page 48 of 68 
Agency for Toxic Substances and Disease Registry (ATSDR) 
Case Studies in Environmental Medicine 
Toxicity  of Polycyclic Aromatic Hydrocarbons (PAHs)  







Please refer to the following Web resources for more information on the 
adverse effects of PAH toxicity, the treatment of PAH-associated 
diseases, and management of persons exposed to PAHs. 
• Agency for Toxic Substances and Disease Registry 
www.atsdr.cdc.gov 
o For chemical, emergency situations 
 CDC Emergency Response:  770-488-7100 and 
request the ATSDR Duty Officer 
o For chemical, non- emergency situations 
 CDC-INFO (www.bt.cdc.gov/coca/800cdcinfo.asp) 
 800-CDC-INFO (800-232-4636) TTY 888-232-6348 - 24 
Hours/Day 
 E-mail: cdcinfo@cdc.gov 
 PLEASE NOTE 
ATSDR cannot respond to questions about individual 
medical cases, provide second opinions or make specific 
recommendations regarding therapy. Those issues 
should be addressed directly with your health care 
provider. 
o Toxicological Profile for Polycyclic Aromatic Hydrocarbons 
www.atsdr.cdc.gov/toxprofiles/tp69.html 
o ToxFAQs™ for Polycyclic Aromatic Hydrocarbons 
www.atsdr.cdc.gov/tfacts69.html 
o Agency for Toxic Substances and Disease Registry Toxic 
Substances and Your Health - Polycyclic Aromatic 
Hydrocarbons (www.atsdr.cdc.gov/substances/PAHs/ 
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o ACOEM is the nation's largest medical society dedicated to promoting 
the health of workers through preventive medicine, clinical care, 
research, and education. 
o Its members are a dynamic group of physicians encompassing 
specialists in a variety of medical practices is united via the College to 
develop positions and policies on vital issues relevant to the practice 
of preventive medicine both within and outside of the workplace. 
• American College of Medical Toxicologists (ACMT) www.acmt.net 
o ACMT is a professional, nonprofit association of physicians with 
recognized expertise in medical toxicology. 
o The College is dedicated to advancing the science and practice of 
medical toxicology through a variety of activities.  
• Association of Occupational and Environmental Clinics www.aoec.org  
o The Association of Occupational and Environmental Clinics (AOEC) is 
a network of more than 60 clinics and more than 250 individuals 
committed to improving the practice of occupational and 
environmental medicine through information sharing and 
collaborative research. 
• Pediatric Environmental Health Specialty Units (PEHSUs) www.pehsu.net 
o Each PEHSU is based at an academic center and is a collaboration 
between the pediatric clinic and the (AOEC) occupational and 
environmental clinic at each site. 
o The PEHSU's have been developed to provide education and 
consultation for health professionals, public health professionals and 
others about the topic of children's environmental health.  
o The PEHSU staff is available for consultation about potential pediatric 
environmental health concerns affecting both the child and the 
family. Health care professionals may contact their regional PEHSU 
site for clinical advice.  
• Poison Control Center 
o The American Association of Poison Control Centers may be contacted 
for questions about poisons and poisonings. The web site provides 
information about poison centers and poison prevention. AAPC does 
not provide information about treatment or diagnosis of poisoning or 
research information for student papers. 
o American Association of Poison Control Centers (1-800-222-1222 or 
www.aapcc.org). 
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Please refer to the following Web resources for general information on 
environmental health. 
• Agency for Toxic Substances and Disease Registry 
www.atsdr.cdc.gov/  
o To view the complete library of CSEMs 
www.atsdr.cdc.gov/csem/. 
o Taking an Exposure History CSEM 
www.atsdr.cdc.gov/csem/exphistory/ 
• Centers for Disease Control and Prevention (CDC) www.cdc.gov  
o CDC works to protect public health and the safety of people, 
by providing information to enhance health decisions, and 
promotes health through partnerships with state health 
departments and other organizations.  
o The CDC focuses national attention on developing and applying 
disease prevention and control (especially infectious diseases), 
environmental health, occupational safety and health, health 
promotion, prevention and education activities designed to 
improve the health of the people of the United States. 
• National Center for Environmental Health (NCEH) 
www.cdc.gov/nceh/ 
o NCEH works to prevent illness, disability, and death from 
interactions between people and the environment. It is 
especially committed to safeguarding the health of populations 
that are particularly vulnerable to certain environmental 
hazards - children, the elderly, and people with disabilities. 
o NCEH seeks to achieve its mission through science, service, 
and leadership. 
• National Institute of Health (NIH) www.nih.gov 
o A part of the U.S. Department of Health and Human Services, 
NIH is the primary Federal agency for conducting and 
supporting medical research. 
• National Institute of Occupational Safety and Health (NIOSH) 
www.cdc.gov/niosh/ 
o NIOSH is in the U.S. Department of Health and Human 
Services and is an agency established to help assure safe and 
healthful working conditions for working men and women by 
providing research, information, education, and training in the 
field of occupational safety and health. 
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• U.S. Department of Labor, Occupational Safety and Health 
Administration (OSHA) www.osha.gov  
o The mission of OSHA  is to assure safe and healthful working 
conditions for working men and women 
• U.S. Environmental Protection Agency www.epa.gov  
o EPA leads the nation's environmental science, research, 
education and assessment efforts. 
o The mission of the Environmental Protection Agency is to 
protect human health and the environment. 
o Since 1970, EPA has been working for a cleaner, healthier 
environment for the American people 
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Assessment and Posttest 
Introduction ATSDR seeks feedback on this course so we can asses its usefulness 
and effectiveness. We ask you to complete the assessment 
questionnaire online for this purpose. 
In addition, if you complete the assessment and posttest online, you 





Accreditation Council for 
Continuing Medical 
Education (ACCME) 
CME: The Centers for Disease Control and Prevention is 
accredited by the Accreditation Council for Continuing Medical 
Education (ACCME) to provide continuing medical education for 
physicians. The Centers for Disease Control and Prevention 
designates this educational activity for a maximum of 2 AMA PRA 
Category 1 Credit(s)™. Physicians should only claim credit 




(ANCC), Commission on 
Accreditation 
CNE: The Centers for Disease Control and Prevention is 
accredited as a provider of Continuing Nursing Education by the 
American Nurses Credentialing Center's Commission on 
Accreditation. This activity provides 2 contact hours. 




CHES: The Centers for Disease Control and Prevention is a 
designated provider of continuing education contact hours 
(CECH) in health education by the National Commission for 
Health Education Credentialing, Inc. This program is a 
designated event for the Certified Health Education Specialist 
(CHES) to receive 2 Category I contact hours in health 
education, CDC provider number GA0082. 
International Association 
for Continuing Education 
and Training (IACET) 
CEU: The CDC has been approved as an Authorized Provider by 
the International Association for Continuing Education and 
Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 
22102. The CDC is authorized by IACET to offer 0.2 IACET CEU's 
for this program. 
 
Disclaimer  CDC, our planners, and our presenters wish to disclose they have no 
financial interests or other relationships with the manufacturers of 
commercial products, suppliers of commercial services, or commercial 
supporters. Presentations will not include any discussion of the unlabeled 
use of a product or a product under investigational use. There was no 
commercial support received for this activity. 
Instructions To complete the assessment and posttest, go to www2.cdc.gov/atsdrce/ 
and follow the instructions on that page. 
You can immediately print your continuing education certificate from 
your personal transcript online.  No fees are charged. 
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 Posttest  
 
There may be 




1. Other names for PAHs include which of the following? 
A. Polynuclear aromatics (PNAs). 
B. Polynuclear hydrocarbons. 
C. Polynuclear aromatic hydrocarbons. 
D. Polycyclic organic matter (POM). 
2. Which of the following statements regarding PAHs is (are) true? 
A. Heavier PAHs (more than 4 rings) tend to adsorb to particulate 
matter. 
B. Lighter PAHs (less than 4 rings) tend to remain gaseous until 
removed via precipitation. 
C. PAH concentration in water tends to be low (around 100 ng/l) due 
to their weak solubility. 
D. PAHs can be absorbed by plants. 
E. PAHs mostly accumulate in soil. 
3. Potential sources of PAH exposure include 
A. Passive inhalation of cigarette smoke. 
B. Motor vehicle exhaust. 
C. Alcoholic beverages. 
D. Inhalation of paint vapors in poorly ventilated area. 
E. Wood stoves for home heating. 
4. Which of the following statements regarding PAHs are FALSE? 
A. PAHs are found only in a small number of industrial settings. 
B. PAHs mostly accumulate in soils. 
C. Benzo[a]pyrene is generally used as an environmental indicator 
for PAHs. 
D. Most PAHs in ambient air are the result of man-made processes. 
5. In non-occupational settings, the majority of PAH exposure in a 
nonsmoking individual comes from which of the following? 
A. Foodstuff ingestion. 
B. Inhalation route. 
C. Dermal route. 
D. Water. 
6. Persons with potentially increased PAH exposure include 
A. Hunters. 
B. Coke oven workers. 
C. Roofing asphalt applicators. 
D. Chimney sweeps. 
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E. Breastfeeding mothers. 
7. Which of the following statements are true about PAHs? 
A. Exposure is most often determined based on patient history. 
B. Direct assays in the body are not clinically useful. 
C. Exposure can cause pancreatitis. 
D. Acute exposure can cause convulsions or unexplained loss of 
consciousness. 
E. The prognosis for most acutely exposed patients is poor. 
8. Which of the following statements regarding OSHA’s standards for 
PAHs is/are FALSE? 
A. OSHA requires workers who are exposed to PAH above the PEL to 
be under medical surveillance. 
B. OSHA requires all workers to be trained in proper use of 
appropriate personal protective equipment and safety. 
C. Purchase of personal protective equipment is the responsibility of 
individual employees. 
D. The OSHA PEL is a legally enforceable standard. 
9. Which of the following statements regarding PAHs in water is/are 
true? 
A. The EPA maximum contaminant level is a legally enforceable 
standard. 
B. The maximum contaminant level is an 8-hour time-weighted 
average. 
C. EPA has set maximum contaminant levels for PAHs in foodstuffs. 
D. EPA developed ambient water quality criteria to protect human 
health from the carcinogenic effects of PAH exposure. 
10. Which of the following regarding the biologic fate of PAHs in the body 
are true? 
A. PAHs are metabolized in a number of organs and excreted in bile 
and urine. 
B. Information on the absorption, distribution, and elimination of 
PAHs in the human body is derived primarily from animal studies. 
C. Generally, PAHs bound to airborne particulate matter are not 
absorbed as well in the lungs as the same dose of PAHs that are 
unbound to particulate matter. 
D. The liver P-450 mixed-function oxidase system is the predominant 
mechanism of PAH metabolism. 
E. 1-Hydroxypryrene is a commonly measured urine metabolite for 
PAH exposure. 
11. The following signs and symptoms can be found in patients 
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E. Cutaneous photosensitization. 
12. The mechanism of PAH-induced carcinogenesis is believed to be 
which of the following? 
A. Covalent binding of PAH metabolites to DNA. 
B. Generation of active oxygen species. 
C. Cell-mediated inflammatory mechanisms. 
D. All of the above. 
13. Reported health effects associated with chronic exposure to coal tar 
and its by-products (e.g., PAH) include 
A. Warts on sun-exposed areas of the skin, with progression to 
cancer. 
B. Irritation of the eyes. 
C. Bronchogenic cancer. 
D. Leukoplakia. 
E. Lymphoma. 
14. In the treatment of patients with PAH exposure, which of the 
following is/are true? 
A. Education and future avoidance of exposure are important. 
B. Continued use of tobacco products should be discouraged. 
C. Treatment of acute exposure is largely symptomatic. 
D. The specific PAH should be determined so that an antidote can be 
prescribed. 
E. A fat biopsy is integral to medical surveillance of PAH-exposed 
patients. 
15. Which of the following should be included in the differential diagnosis 
of a patient suffering from the chronic effects of PAH exposure? 
A. Pancytopenia. 
B. Hepatic angiosarcoma. 
C. Pancreatitis. 
D. Tuberculosis. 
E. Lung abscess. 
16. Regarding PAH distribution, metabolism, and excretion, which are 
true? 
A. The liver and kidney are both involved in metabolism. 
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B. Binding of PAH metabolites to DNA is believed to be the 
mechanism of PAH-induced carcinogenesis. 
C. Metabolized PAHs cannot be eliminated by hepatobiliary excretion. 
D. Excretion is through bile and urine. 
E. Calcium EDTA chelation enhances PAH excretion. 
17. Which of the following statements is (are) true? 
A. Management of a worker exposed to PAHs includes bone marrow 
aspiration. 
B. PAH metabolites can cross the placental barrier. 
C. Acutely exposed skin should be decontaminated by gently 
scrubbing with a 10% iodine solution. 
D. Hair analysis can reveal past PAH exposure. 
E. The bay region theory attempts to explain why PAHs are found in 
bay waters. 
18. What steps can patients take to reduce the risk of overexposure to 
PAHs? 
A. Minimize hobby and recreational PAH exposures. 
B. Avoid exposure to all forms of smoke. 
C. Stop smoking. 
D. Minimize dietary PAH exposure. 
E. All of the above. 
Relevant 
Content 
To review content relevant to the post-test questions, see: 
 
Question Location of Relevant Content 
1 What are PAHs? 
2 What are PAHs? 
Where are PAHs found? 
3 Where are PAHs found? 
4 Where are PAHs found? 
5 What are routes of exposure for PAHs? 
6 Who is at risk of PAH exposure? 
7 Clinical Assessment 
8 What are standards and regulations for PAH exposure? 
9 What are standards and regulations for PAH exposure? 
10 What is the biologic fate of PAHs in the body? 
11 Clinical assessment 
12 How do PAHs induce pathogenic changes? 
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13 What health effects are associated with PAH exposure? 
14 How should patients exposed to PAHs be treated and managed? 
15 Clinical assessment 
16 What is the biologic fate of PAHs? 
How do PAHs induce pathogenic changes? 
17 What are routes of exposure for PAHs? 
18 What instructions should be given to patients exposed to PAHs? 
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